Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1037-1040

  Pandie, Mishal ^a   Wiesner, Lubbe ^a   McIlleron, Helen ^a   Hughes, Jennifer ^b   Siwendu, Sweetness ^c   Conradie, Francesca ^d,e   Variava, Ebrahim ^d   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Brooklyn Chest Hospital   (South Africa)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CYTOCHROME P450 3A4; DRUG METABOLITE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; DRUG COMBINATION; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; QUINOLINE DERIVATIVE; RITONAVIR; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESISTANT TUBERCULOSIS; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PHARMACOKINETIC PARAMETERS; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG COMBINATION; DRUG INTERACTION; DRUG MONITORING; HIV INFECTIONS; MICROBIOLOGY; TIME FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIROLOGY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; NEVIRAPINE; RITONAVIR; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84964407318     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv447     Document Type: Article

References (13)

1. Van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 2014; 69: 2310-8.
2. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
3. Uthman OA, Okwundu C, Gbenga K et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med 2015; 163: 32-9.
4. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. June 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/.
5. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S8-14.
6. Wyen C, Fuhr U, Frank D et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84: 75-82.
7. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir/ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB/HIV co-infection. Antimicrob Agents Chemother 2014; 58: 6406-12.
8. Ndjeka N, Conradie F, Schnippel K et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-85.
9. Center for Drug Evaluation and Research, FDA. Guidance for Industry: Bioanalytical Method Validation. September 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
10. EMA. Guideline on Bioanalytical Method Validation. 21 July 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
11. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
12. TM Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf.
13. WHO. Companion Handbook to theWHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2014. http://www.who.int/tb/publications/pmdt_companionhandbook/en/.